Spartan Micro

Executive Summary

Spartan Micro is a private medical device company headquartered in San Francisco, developing innovative endovascular treatments for cerebrovascular and peripheral vascular diseases. Founded in 2017, the company is transitioning to production of its flagship Spartan eCoil™ System, a next-generation embolic coil designed to improve clinical outcomes for interventional neuroradiologists, neurosurgeons, and vascular surgeons. Targeting regulatory clearances in Europe, North America, and Asia, Spartan Micro addresses a sizable market opportunity in neurovascular interventions, where minimally invasive devices are increasingly preferred. With a focused product pipeline and a clear path to commercialization, the company is positioned to capture share in the growing global neurovascular device market, projected to exceed $3 billion by 2027. The company's immediate priority is obtaining regulatory approvals to commence sales. While specific financial details and total funding remain undisclosed, the shift from development to production signals operational maturity. Key risks include regulatory timelines, competitive dynamics with established players like Medtronic and Stryker, and the need for commercial execution. However, the unique design of the eCoil System and the experienced management team provide a differentiated value proposition. Spartan Micro's success hinges on securing initial clearances and building distribution partnerships, which could drive rapid adoption in key regions. The next 12–18 months are critical for validating the technology and establishing a commercial footprint.

Upcoming Catalysts (preview)

• Q4 2026CE Mark Approval for Spartan eCoil System55% success
• Q1 2027FDA 510(k) Submission for US Market45% success
• Q2 2026Strategic Partnership or Distribution Agreement in Asia40% success